JSAM
RYTM icon

J. Safra Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

J. Safra Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20
Closed -$2.02K – 673
2025
Q3 		$2.02K Buy
+20
New +$1.86K ﹤0.01% 403

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

J. Safra Asset Management's RYTM Position: Q4 2025 in Review

J. Safra Asset Management sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 20 shares — an estimated $2.02K sold.

J. Safra Asset Management first reported a position in RYTM in Q3 2025 and held it in 1 quarter. The position peaked at $2.02K in Q3 2025. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

  • J. Safra Asset Management reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • J. Safra Asset Management sold 20 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $2.02K.
  • J. Safra Asset Management first reported a position in Rhythm Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • J. Safra Asset Management's Rhythm Pharmaceuticals position peaked at $2.02K in Q3 2025.
  • 279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on J. Safra Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.